Shots:

• The US FDA has granted ODD to the OBI-999 for the treatment of gastric cancer. This marks the second ODD to the therapy as it has already received the FDA’s ODD to treat pancreatic cancer on Dec 26- 2019
• The US FDA grants ODD to therapies intended to treat- diagnose or prevent rare diseases or disorders affecting fewer than 200-000 people in the US
• OBI-999 is a novel ADC in combination with a validated payload (MMAE) and the antibody targeting Globo H- currently being evaluated in P-I/II clinical study and has demonstrated tumor shrinkage in its preclinical studies

Click here ­to­ read full press release/ article | Ref:  OBI Pharma | Image:  OBI Pharma